Loading…
Reported covered position: LA, Sen. Crapo & Rep. Toomey; LA & Press Sec. Rep. Norwood
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2020 · first_quarter · 1A
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2020 · first_quarter · Q1
Source: Senate LDA
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION |
| 26 |
| 2014–2019 |
| ACHAOGEN | 25 | 2013–2018 |
| AMGEN | 24 | 2014–2019 |
| ANTIMICROBIAL INNOVATION ALLIANCE | 21 | 2013–2020 |
| NOVARTIS | 21 | 2015–2019 |
| GENENTECH | 20 | 2015–2020 |
| ELI LILLY AND COMPANY | 19 | 2013–2017 |
| STRAND DIAGNOSTICS | 19 | 2015–2019 |
| zimmer biomet | 19 | 2015–2019 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 18 | 2016–2020 |
| AMERICAN MEDICAL ASSOCIATION | 16 | 2013–2016 |
| NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) | 14 | 2017–2019 |
| WEX HEALTH | 13 | 2013–2019 |
| BREATHE TECHNOLOGIES INC. | 12 | 2014–2016 |
| HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) | 12 | 2017–2020 |
| MERCK AND CO INC | 11 | 2013–2015 |
| ALLERGAN PLC | 10 | 2013–2015 |
| ASTELLAS PHARMA US, INC. | 10 | 2013–2015 |
| ASTRAZENECA | 10 | 2013–2015 |
| GLAXOSMITHKLINE | 10 | 2013–2015 |
| ALNYLAM PHARMACEUTICALS | 8 | 2018–2020 |
| DENDREON PHARMACEUTICALS, LLC | 7 | 2019–2020 |
| EGALET US INC. | 7 | 2017–2018 |
| PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) | 7 | 2018–2019 |
| JOHNSON & JOHNSON | 6 | 2014–2015 |
| NASH ALLIANCE LLC | 6 | 2019–2020 |
| AMERICAN OCCUPATIONAL THERAPY ASSOCIATION | 5 | 2014–2016 |
| NATIONAL ASSOCIATION OF SPECIALTY PHARMACY (NASP) | 5 | 2017 |
| AMERICAN LUNG ASSOCIATION | 4 | 2018–2019 |
| Caris Life Sciences, Inc. | 4 | 2014 |
| MATRIX MEDICAL NETWORK | 4 | 2013–2014 |
| XOMA Corporation | 4 | 2015 |
| IVX HEALTH | 3 | 2019 |
| MICROBION CORPORATION | 3 | 2015 |
| RADIATION THERAPY ALLIANCE | 3 | 2015 |
| SPERO OPCO, INC. | 3 | 2015 |
| TETRAPHASE PHARMACEUTICALS | 3 | 2015 |
| THE MEDICINES COMPANY | 3 | 2015 |
| ZAVANTE THERAPEUTICS, INC. | 3 | 2015 |
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Lower Costs, More Cures Act of 2019
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Prescription Drug Pricing Reduction Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Prescription Drug Pricing Reduction Act of 2019
Client: EMD SERONO, INC. · Firm: THE MCMANUS GROUP
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Lower Costs, More Cures Act of 2019
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Support of proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102; and H.R. 19, the Lower Costs, More Cures Act of 2019.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102.
Removing Barriers to Colorectal Cancer Screening Act of 2020
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage.
Further Consolidated Appropriations Act, 2020
Client: STRAND DIAGNOSTICS · Firm: THE MCMANUS GROUP
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, H.R. 3429, the HEARTS and Rural Relief Act, and H.R. 1865, the Further Consolidated Appropriations Act.
Further Consolidated Appropriations Act, 2020
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices. Support for medical device excise tax repeal in H.R. 1865, the Further Consolidated Appropriations Act.
Further Consolidated Appropriations Act, 2020
Client: ZIMMER BIOMET · Firm: THE MCMANUS GROUP
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 and H.R. 1865, the Further Consolidated Appropriations Act.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare Part B reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019. International Pricing Index model (83 FR 54546).
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Lower Costs, More Cures Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143. Proposed Radiation Oncology (RO) Model, 84 FR 34478. Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
Access and reimbursement for Part B and Part D drugs. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Lower Costs, More Cures Act of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Support of proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102; and H.R. 19, the Lower Costs, More Cures Act of 2019.
Lower Costs, More Cures Act of 2019
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Lower Costs, More Cures Act of 2019
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Lower Costs, More Cures Act of 2019
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19, the Lower Costs, More Cures Act of 2019.
Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform in H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Prescription Drug STAR Act
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Modernizing device coverage, coding, and payment. H.R. 2113, the Prescription Drug STAR Act.
Access and reimbursement for Part B and Part D drugs. Opposition to step therapy requirement in Medicare Advantage. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform. H.R. 2113, the Prescription Drug STAR Act.
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Part B reform. H.R. 2113, the Prescription Drug STAR Act.
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Part B reform. H.R. 2113, the Prescription Drug STAR Act.
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. H.R. 2113, Prescription Drug STAR Act of 2019. S. 551, the REFUND Act of 2019.
Prescription Drug STAR Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113. 84 FR 2340, CFR: 42 CFR 1001, RIN: 0936-AA08 - to amend the safe harbor regulation concerning discounts, which are defined as certain conduct that is protected from liability under the Federal anti-kickback statute, section 1128B(b) of the Social Security Act.
H.R. 2113, the Prescription Drug STAR Act.
Prescription Drug STAR Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. H.R. 2113, the Prescription Drug STAR Act.
Access and reimbursement for Part B and Part D drugs. Opposition to step therapy requirement in Medicare Advantage. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Prescription Drug STAR Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
PIMA of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102.
PIMA of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
PIMA of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. Proposed Radiation Oncology (RO) Model, 84 FR 34478. S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
PIMA of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Support of proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102; and H.R. 19, the Lower Costs, More Cures Act of 2019.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143. Proposed Radiation Oncology (RO) Model, 84 FR 34478. Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 and H.R. 1865, the Further Consolidated Appropriations Act.
Protect Medical Innovation Act of 2019
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices. Support for medical device excise tax repeal in H.R. 1865, the Further Consolidated Appropriations Act.
Protect Medical Innovation Act of 2019
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for S. 692 - Protection Medical Innovation Act of 2019. Support for H.R. 2207 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019.
Protect Medical Innovation Act of 2019
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Protect Medical Innovation Act of 2019
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for S. 692 - Protection Medical Innovation Act of 2019. Support for H.R. 2207 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Protect Medical Innovation Act of 2019
Client: MEDICAL DEVICE MANUFACTURERS ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Medicare Care Coordination Improvement Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. Proposed Radiation Oncology (RO) Model, 84 FR 34478. S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Medicare Care Coordination Improvement Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Medicare Care Coordination Improvement Act of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Medicare Care Coordination Improvement Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Medicare Care Coordination Improvement Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143. Proposed Radiation Oncology (RO) Model, 84 FR 34478. Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
Medicare Care Coordination Improvement Act of 2019
Client: LARGE UROLOGY GROUP PRACTICE ASSOCIATION · Firm: THE MCMANUS GROUP
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Medicare Care Coordination Improvement Act of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Support of proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102; and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare Care Coordination Improvement Act of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102.
Medicare Care Coordination Improvement Act of 2019
Client: NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) · Firm: THE MCMANUS GROUP
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers. Support H.R. 2282/S. 966, the Medicare Care Coordination Improvement Act.
Medicare Care Coordination Improvement Act of 2019
Client: DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. · Firm: THE MCMANUS GROUP
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage.
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, and H.R. 3429, the HEARTS and Rural Relief Act.
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, H.R. 3429, the HEARTS and Rural Relief Act, and H.R. 1865, the Further Consolidated Appropriations Act.
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, and H.R. 3429, the HEARTS and Rural Relief Act.
Access and reimbursement for Part B and Part D drugs. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and S.2543, the Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Medicare Part B reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019. International Pricing Index model (83 FR 54546).
Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform in H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare Part B drugs payments and access. S. 551, the REFUND Act, S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Access and reimbursement for Part B and Part D drugs. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform in H.R. 3, the Lower Drug Costs Now Act of 2019, and S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES, INC. · Firm: THE MCMANUS GROUP
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GILEAD SCIENCES, INC. · Firm: THE MCMANUS GROUP
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: DENDREON PHARMACEUTICALS LLC · Firm: THE MCMANUS GROUP
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALNYLAM PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ALNYLAM PHARMACEUTICALS · Firm: THE MCMANUS GROUP
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 2543, the Prescription Drug Pricing Reduction Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: THE MCMANUS GROUP
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) · Firm: THE MCMANUS GROUP
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Medicare Part B reform. S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act. International Pricing Index model (83 FR 54546).
Medicare Part D reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASH ALLIANCE LLC via THE MCMANUS GROUP
2020 · first_quarter · 1T
Policies regarding research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
ANTIMICROBIAL INNOVATION ALLIANCE via THE MCMANUS GROUP
2020 · first_quarter · 1T
Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives.
Medicare payment for inpatient antibiotics.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2020 · first_quarter · Q1
Access and reimbursement in Parts B & D. Part D redesign. Lobbied against the International Pricing Index model (83 FR 54546).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2020 · first_quarter · Q1
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2020 · first_quarter · Q1
Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform. Home administration of injectable and infusible drugs including in CMS-1744-IFC.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2020 · first_quarter · Q1
General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2020 · first_quarter · Q1
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2020 · first_quarter · Q1
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN INC via THE MCMANUS GROUP
2020 · first_quarter · Q1
Medicare Parts B and D drugs payments and access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · 1A
Support for S. 692 - Protection Medical Innovation Act of 2019. Support for H.R. 2207 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · 1A
Support for reforming the United States Preventive Services Task Force.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2019 · fourth_quarter · 4A
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2019 · third_quarter · 3A
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Surprise billing reform, including S. 1895, the Lower Health Care Costs Act, and H.R. 3630, the No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform in H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Reform of the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Q4
Access and reimbursement for Part B and Part D drugs. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Support for 340B reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Pharmaceutical policy as it relates to payments under the 340B program.
Funding for HCV and public health activities via appropriations.
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
STRAND DIAGNOSTICS via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, H.R. 3429, the HEARTS and Rural Relief Act, and H.R. 1865, the Further Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASH ALLIANCE LLC via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Policies regarding research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Modernizing device coverage, coding, and payment. The Radiation Oncology (RO) Model: 84 FR 34478, 42 CFR 512.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices. Support for medical device excise tax repeal in H.R. 1865, the Further Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives.
Medicare payment for inpatient antibiotics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN INC via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Support for H.R.4350/S. 3085, The Ambulatory Surgical Center Quality and Access Act of 2019, and legislation to tie ambulatory surgery center payment updates to the hospital market basket. H.R. 3429, the HEARTS and Rural Relief Act of 2019. Increase patient access to procedures in ASCs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEX HEALTH via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Opposition to S. 2839, the Eliminating Corporate Shadow Banking Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Access to and reimbursement of pharmaceuticals in the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 and H.R. 1865, the Further Consolidated Appropriations Act.
S. 1842, Protecting Personal Health Data Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IVX HEALTH via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Medicare Part B reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019. International Pricing Index model (83 FR 54546).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers.
Surprise billing reform, including H.R 3630, the No Surprises Act, and S. 1895, the Lower Health Care Costs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143. Proposed Radiation Oncology (RO) Model, 84 FR 34478. Support for proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducement (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19/ S.3129, the Lower Costs, More Cures Act of 2019.
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via THE MCMANUS GROUP
2019 · fourth_quarter · 4T
Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act, H.R. 19, the Lower Costs, More Cures Act of 2019, and H.R. 3, the Lower Drug Costs Now Act.
Advocacy regarding access to 340B reimbursement.
Legislation amending the Patent Act, including reforms to patent eligible subject matter. S. 1416, the Affordable Prescriptions for Patients Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and H.R. 19, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2019 · fourth_quarter · Q4
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Support of proposed rules, Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations (84 FR 55766) and Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements (84 FR 55694). S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102; and H.R. 19, the Lower Costs, More Cures Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2019 · third_quarter · Q3
Support for surprise billing reform, including S. 1895, the Lower Health Care Costs Act, and H.R. 3630, the No Surprises Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via THE MCMANUS GROUP
2019 · third_quarter · Q3
Legislation amending the Patent Act, including reforms to patent eligible subject matter. S. 1416, the Affordable Prescriptions for Patients Act of 2019.
Advocacy regarding access to 340B reimbursement.
Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2019 · third_quarter · Q3
Funding for HCV and public health activities via appropriations.
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
2019 · third_quarter · Q3
Access and reimbursement for Part B and Part D drugs. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and S.2543, the Prescription Drug Pricing Reduction Act of 2019.
Support for 340B reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2019 · third_quarter · 3A
Access and reimbursement in Part D and Part B. S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Access to and reimbursement of pharmaceuticals in the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2019 · third_quarter · Q3
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). H.R. 3, the Lower Drug Costs Now Act of 2019, and S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Legislation involving reforms to patent eligible subject matter under section 101. S. 1416, the Affordable Prescriptions for Patients Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2019 · third_quarter · Q3
Reform of the 340B program.
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Parts B and D reform in H.R. 3, the Lower Drug Costs Now Act of 2019, and S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IVX HEALTH via THE MCMANUS GROUP
2019 · third_quarter · Q3
Medicare Part B reform. S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act. International Pricing Index model (83 FR 54546).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2019 · third_quarter · Q3
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, and H.R. 3, the Lower Drug Costs Now Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2019 · third_quarter · Q3
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 2543, the Prescription Drug Pricing Reduction Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2019 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers.
Support for surprise billing reform, including H.R 3630, the No Surprises Act, and S. 1895, the Lower Health Care Costs Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2019 · third_quarter · Q3
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers.
Support for surprise billing reform, including H.R 3630, the No Surprises Act, and S. 1895, the Lower Health Care Costs Act; and
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2019 · third_quarter · Q3
S. 1842, Protecting Personal Health Data Act.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRAND DIAGNOSTICS via THE MCMANUS GROUP
2019 · third_quarter · Q3
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, and H.R. 3429, the HEARTS and Rural Relief Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2019 · third_quarter · Q3
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. S. 2543, the Prescription Drug Pricing Reduction Act of 2019, sec. 102.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN INC via THE MCMANUS GROUP
2019 · third_quarter · Q3
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Medicare Part B drugs payments and access. S. 551, the REFUND Act, S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2019 · third_quarter · Q3
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. OPPS/ ASC Proposed Payment Rule, (84 FR 39398). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law. Proposed Radiation Oncology (RO) Model, 84 FR 34478. S. 2543, the Prescription Drug Pricing Reduction Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2019 · third_quarter · Q3
General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in H.R. 3, the Lower Drug Costs Now Act, and S. 2543, the Prescription Pricing Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via THE MCMANUS GROUP
2019 · third_quarter · Q3
Medicare payment for inpatient antibiotics.
Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASH ALLIANCE LLC via THE MCMANUS GROUP
2019 · third_quarter · Q3
Policies regarding research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2019 · third_quarter · Q3
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Modernizing device coverage, coding, and payment. The Radiation Oncology (RO) Model: 84 FR 34478, 42 CFR 512.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2019 · third_quarter · Q3
Support for H.R.4350, The Ambulatory Surgical Center Quality and Access Act of 2019 and legislation to tie ambulatory surgery center payment updates to the hospital market basket. H.R. 3429, the HEARTS and Rural Relief Act of 2019. Increase patient access to procedures in ASCs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NASH ALLIANCE LLC via THE MCMANUS GROUP
2019 · second_quarter · 2A
Policies regarding research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
NASH ALLIANCE LLC via THE MCMANUS GROUP
2019 · first_quarter · 1A
Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NASH ALLIANCE LLC via THE MCMANUS GROUP
2019 · first_quarter · RR
Issues regarding non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
Issues regarding non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
Issues regarding non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
IVX HEALTH via THE MCMANUS GROUP
2019 · third_quarter · RR
Medicare Part B payment reform.
DENDREON PHARMACEUTICALS LLC via THE MCMANUS GROUP
2019 · third_quarter · RR
Medicare Part B payment reform.
ANTIMICROBIAL INNOVATION ALLIANCE via THE MCMANUS GROUP
2019 · second_quarter · Q2
Medicare payment for inpatient antibiotics.
Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via THE MCMANUS GROUP
2019 · second_quarter · Q2
Pharmaceutical coverage and access in Parts A, B, C, and D.
Advocacy regarding access to 340B reimbursement.
Legislation amending the Patent Act, including reforms to patent eligible subject matter. S. 1416, the Affordable Prescriptions for Patients Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2019 · second_quarter · Q2
Support legislation to tie ambulatory surgery center payment updates to the hospital market basket. H.R. 3429, the HEARTS and Rural Relief Act of 2019. Increase patient access to procedures in ASCs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2019 · second_quarter · Q2
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Part B reform. H.R. 2113, the Prescription Drug STAR Act.
Reform of the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2019 · second_quarter · Q2
Legislation involving reforms to patent eligible subject matter under section 101. S. 1416, the Affordable Prescriptions for Patients Act of 2019.
Access and reimbursement in Parts B & D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113. 84 FR 2340, CFR: 42 CFR 1001, RIN: 0936-AA08 - to amend the safe harbor regulation concerning discounts, which are defined as certain conduct that is protected from liability under the Federal anti-kickback statute, section 1128B(b) of the Social Security Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2019 · second_quarter · Q2
Modernizing device coverage, coding, and payment. H.R. 2113, the Prescription Drug STAR Act.
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019 - to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2019 · second_quarter · Q2
Pharmaceutical policy as it relates to payments under the 340B program.
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412).
2019 · second_quarter · Q2
Access and reimbursement for Part B and Part D drugs. Opposition to step therapy requirement in Medicare Advantage. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Support for 340B reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2019 · second_quarter · Q2
Support for surprise billing reform, including H.R. 3502, to amend the Public Health Service Act and title XI of the Social Security Act to protect health care consumers from surprise billing practices, and for other purposes; H.R. 3630, the No Surprises Act; S. 1895, the Lower Health Care Costs Act; and S. 1531, the Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2019 · second_quarter · Q2
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. Commented on Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2019 · second_quarter · Q2
Support H.R. 3534, the USPSTF Transparency Accountability Act of 2019.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes. Stark Law RFI, CMS-1720-NC regarding the physician self-referral law.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLERGAN INC via THE MCMANUS GROUP
2019 · second_quarter · Q2
Medicare Part B drugs payments and access. S. 551, the REFUND Act.
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2019 · second_quarter · Q2
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform. H.R. 2113, the Prescription Drug STAR Act.
General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2019 · second_quarter · Q2
Access to and reimbursement of pharmaceuticals in the 340B program.
Access and reimbursement in Part D and Part B. H.R. 2113, the Prescription Drug STAR Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2019 · second_quarter · Q2
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. H.R. 2113, Prescription Drug STAR Act of 2019. S. 551, the REFUND Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2019 · second_quarter · Q2
Support for H.R. 2207/S. 692 - Protect Medical Innovation Act of 2019.
H.R. 2113, the Prescription Drug STAR Act.
S. 1842, Protecting Personal Health Data Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRAND DIAGNOSTICS via THE MCMANUS GROUP
2019 · second_quarter · Q2
Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, and H.R. 3429, the HEARTS and Rural Relief Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2019 · second_quarter · Q2
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers. Support H.R. 2282/S. 966, the Medicare Care Coordination Improvement Act.
Support for surprise billing reform, including H.R. 3502, to amend the Public Health Service Act and title XI of the Social Security Act to protect health care consumers from surprise billing practices, and for other purposes; H.R 3630, the No Surprises Act; S. 1895, the Lower Health Care Costs Act; and S. 1531, the Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · first_quarter · Q1
Support for 340B reform.
Access and reimbursement for Part B and Part D drugs. Opposition to step therapy requirement in Medicare Advantage. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via THE MCMANUS GROUP
2019 · first_quarter · Q1
Medicare payment for inpatient antibiotics.
Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN LUNG ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · 1T
Sec. VII of the proposed rule for the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program for Calendar Year 2019 (RIN 0938-AT28).
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ZIMMER BIOMET via THE MCMANUS GROUP
2019 · first_quarter · Q1
Improve the process for inspections of device establishments for granting export certifications.
Support for S. 692 - Protection Medical Innovation Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STRAND DIAGNOSTICS via THE MCMANUS GROUP
2019 · first_quarter · Q1
Support for Medicare coverage of prostate cancer diagnostic test.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via THE MCMANUS GROUP
2019 · first_quarter · Q1
Pharmaceutical coverage and access in Parts A, B, C, and D.
Advocacy regarding access to 340B reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF FREESTANDING EMERGENCY CENTERS (NAFEC) via THE MCMANUS GROUP
2019 · first_quarter · Q1
Support for surprise billing reform.
Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via THE MCMANUS GROUP
2019 · first_quarter · Q1
Access and reimbursement in Part D. Part D implementation. Lobbied against the International Pricing Index model (83 FR 54546). The Prescription Drug STAR Act, H.R. 2113.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PEDIATRIX MEDICAL GROUP (MEDNAX NATIONAL MEDICAL GROUP) via THE MCMANUS GROUP
2019 · first_quarter · Q1
Expanding Veterans Health Administration coverage to non-employed physicians.
Surprise Billing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · Q1
Support for S. 692 - Protection Medical Innovation Act of 2019. Support for H.R. 2207 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LARGE UROLOGY GROUP PRACTICE ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · Q1
Support for reforming the United States Preventive Services Task Force.
Support for H.R. 2282 / S. 966 - Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage. CY 2019 OPPS/ ASC Proposed Payment Rule, (83 Fed. Reg. 37046). Lobbied against the International Pricing Index model (83 FR 54546). Support site neutrality proposals. Oppose H.R. 2143 - To prevent wasteful and abusive billing of ancillary services to the Medicare program, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA, INC. (FORMERLY KNOWN AS HORIZON PHARMA USA, INC.) via THE MCMANUS GROUP
2019 · first_quarter · Q1
Access and reimbursement in Part D and Part B.
Access to and reimbursement of pharmaceuticals in the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
GILEAD SCIENCES, INC. via THE MCMANUS GROUP
2019 · first_quarter · Q1
Pharmaceutical policy as it relates to payments under the 340B program.
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including regulation "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Spending" (RIN 0938-AT92).
Funding for HCV and public health activities via appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via THE MCMANUS GROUP
2019 · first_quarter · Q1
Reform of the 340B program.
Opposition to step therapy requirement in Medicare Advantage. Opposed the International Pricing Index model (83 FR 54546). Medicare Part B reform. H.R. 2113, the Prescription Drug STAR Act.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
EMD SERONO, INC. via THE MCMANUS GROUP
2019 · first_quarter · Q1
General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.
Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. via THE MCMANUS GROUP
2019 · first_quarter · Q1
H.R. 1570 / S. 668 - Removing Barriers to Colorectal Cancer Screening Act of 2019. Opposition to H.R. 2143 - Promoting Integrity in Medicare Act of 2019. Support for H.R. 2282 / S. 966 Medicare Care Coordination Improvement Act of 2019. Opposition to step therapy requirement in Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMBULATORY SURGERY CENTER ASSOCIATION via THE MCMANUS GROUP
2019 · first_quarter · Q1
Support legislation to tie ambulatory surgery center payment updates to the hospital market basket.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS via THE MCMANUS GROUP
2019 · first_quarter · Q1
Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act of 2018.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmaceutical policy as it relates to payments under the 340B program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Funding for HCV and public health activities via appropriations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE